Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

5.28
-0.1300-2.40%
Pre-market: 5.290.0100+0.19%04:08 EDT
Volume:1.53M
Turnover:8.18M
Market Cap:439.27M
PE:-4.09
High:5.62
Open:5.46
Low:5.23
Close:5.41
52wk High:7.07
52wk Low:1.41
Shares:83.20M
Float Shares:64.45M
Volume Ratio:0.42
T/O Rate:2.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2925
EPS(LYR):-0.8000
ROE:-4796.52%
ROA:-48.06%
PB:-33.83
PE(LYR):-6.60

Loading ...

Longeveron - Marie Washburn Steps Down as CFO, Returns to Corporate Controller Role

THOMSON REUTERS
·
Aug 20

Opus Genetics Grants Options for 310,000 Shares Under Inducement Plan

Reuters
·
Aug 20

Opus Genetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 20

Opus Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Opus Genetics (IRD) Receives a Buy from Piper Sandler

TIPRANKS
·
Aug 07

Cantor Fitzgerald Sticks to Their Buy Rating for Opus Genetics (IRD)

TIPRANKS
·
Aug 07

RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 07

Opus Genetics Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Opus Genetics - May Offer and Sell up to $300 Mln of Securities - SEC Filing

THOMSON REUTERS
·
Aug 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 07

Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate

Benzinga Earnings
·
Aug 06

Opus Genetics Q2 FY26 Net Loss Widens to $8.1 Million; Revenue Drops to $755,000

Reuters
·
Aug 06

Opus Genetics Inc Q2 Pretax Profit USD -8.098 Million

THOMSON REUTERS
·
Aug 06

Press Release: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Dow Jones
·
Aug 06

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 04

Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder

MT Newswires Live
·
Aug 03

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of Opgx-Lca5 for Lca5-Associated Inherited Retinal Disease

THOMSON REUTERS
·
Aug 03

Opus Genetics - May Submit Bla Based on Six-Month Efficacy Data

THOMSON REUTERS
·
Aug 03

Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)

TIPRANKS
·
Jul 31

TD Cowen Initiates Opus Genetics at Buy

MT Newswires Live
·
Jul 29